Brain delivery of lipid nanoparticles with shuttle peptides
Advances in Pharmacology · 2026
DOI: 10.1016/bs.apha.2026.02.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Pharmacology, 2026. Verfasst von Noelia Martinez-Martinez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain; Departm…. Hauptthemen laut MEDLINE: Nanoparticles, Brain, Lipids, Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 251 Literaturangaben. Gefördert von: Universidad de Costa Rica, Ministerio de Ciencia, Innovación y Universidades.
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) have gained growing attention as advanced drug delivery systems capable of addressing major challenges in the development of innovative therapies. They have been widely investigated to overcome the challenges of development delivery strategies for the Central Nervous System (CNS). Their small size, biomimetic lipid composition, and modifiable surface properties make them promising candidates for targeting the Blood Brain Barrier (BBB), leading to improved therapeutic interventions. This chapter provides an integrative overview of the main classes of LNPs and their manufacturing methods, offering insights into their design, characterization, and optimization for brain delivery. We first discuss the key physicochemical parameters -particle size, polydispersity index, surface charge, shape, crystallinity, and encapsulation efficiency- and their impact on biodistribution, stability, and BBB penetration. Formulation and manufacturing strategies are examined, from conventional approaches to microfluidic mixing. Special attention is given to surface modification strategies, including ligand conjugation and the technological variables influencing receptor-specific transport that determine brain targeting. We place particular emphasis on brain-shuttle peptides, which constitute the most widely employed approach for functionalizing LNPs. Finally, we summarize representative preclinical studies, emerging clinical trials, and key translational challenges -such as neurotoxicity, batch-to-batch reproducibility, and regulatory hurdles-, but also highlight the proved potential of LNPs to achieve successful clinical translation in other therapeutic areas. These advances provide valuable insights and technical precedents that may benefit the development of LNP-based therapeutics for CNS disorders, supporting future strategies targeting neurological and psychiatric disorders as well as brain tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain; Department of Molecular Biology, Institute of Parasitology and Biomedicine "L…
- Department of Pharmacy and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
- Department of Industrial Pharmacy, Faculty of Pharmacy, University of Costa Rica, San José, Costa Rica; Pharmaceutical Research Institute (INIFAR), Faculty of Pharmacy, University of Costa Rica, San José, Costa Rica. El…
- Department of Cell Biology and Immunology, Institute of Parasitology and Biomedicine "López-Neyra" (IPBLN-CSIC), Granada, Spain.
- Department of Pharmacy and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain; Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Research Grou…
- Department of Molecular Biology, Institute of Parasitology and Biomedicine "López-Neyra" (IPBLN-CSIC), Granada, Spain.
Förderung
- Universidad de Costa Rica
- Ministerio de Ciencia, Innovación y Universidades
Zitieren
APA
Martinez-Martinez, N., Carrera-Rodríguez, L., Vargas, R., Hernández-Munain, C., Suñé-Pou, M., & Suñé, C. (2026). Brain delivery of lipid nanoparticles with shuttle peptides. Advances in Pharmacology. https://doi.org/10.1016/bs.apha.2026.02.005
Vancouver
Martinez-Martinez N, Carrera-Rodríguez L, Vargas R, Hernández-Munain C, Suñé-Pou M, Suñé C. Brain delivery of lipid nanoparticles with shuttle peptides. Advances in Pharmacology. 2026. doi:10.1016/bs.apha.2026.02.005
BibTeX
@article{MartinezMartinez2026,
author = {Martinez-Martinez, Noelia and Carrera-Rodríguez, Laura and Vargas, Ronny and Hernández-Munain, Cristina and Suñé-Pou, Marc and Suñé, Carles},
title = {Brain delivery of lipid nanoparticles with shuttle peptides},
journal = {Advances in Pharmacology},
year = {2026},
doi = {10.1016/bs.apha.2026.02.005}
}
EUVIMED